anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Long-term outcome after surgical treatment of supratentorial ependymoma (STE) in children has not been extensively reported.
FINDINGS: We identified 26 children who underwent primary tumor resection of STE between 1953 and 2011, with at least 8 years follow-up. Ten patients (38%) had anaplastic and 16 had low grade ependymoma. Four of 15 children (26%) treated in the years 1953-1976 survived more than 5 years, but the observed 10-year survival was only 7%. One patient lived for 37 years, and second surgery for a local recurrent lesion disclosed a glioblastoma, possibly secondary to radiotherapy. In contrast, the observed 5-year survival rate for 11 children treated in the years 1992-2011 was 8/11 (73%) and observed 10- and 25-year survival rates were 70% and 66%, respectively. Eight patients were alive and tumor-free with follow-up periods of 8-27 (median 18) years, all treated after 1992. Five of these long-term survivors were 23-39 years old with full-time (n = 3) or part-time (n = 2) work. The last three patients were still children (9-12 years old): one with good function and two with major neurological deficits. The majority of patients (n = 18) received adjuvant radiotherapy and eight children no adjuvant treatment. Repeated resections for residual or recurrent tumor were necessary in 11 patients (42%), mostly due to local disease with progressive clinical symptoms. Eight patients underwent only one repeat resection, whereas three patients had two or more repeat resections within 18 years after initial surgery. Four patients were tumor-free after repeated resections at the latest follow-up, 2-13 years after last surgery.
CONCLUSION: Pediatric STE has a marked risk for local recurrence even after gross total resection and postoperative radiotherapy, but survival has increased following the introduction of modern treatment in recent years. Repeated surgery is an important part of treatment and may lead to persistent tumor control.
PURPOSE: A method for removing pigment of red beet and enhancing physiological activity by radiation is provided to be used in a cosmetic, medicinal, or health food composition. CONSTITUTION: A method for removing pigment and maintaining physiological activity of red beet extract comprises a step of irradiating radiation to the red beet extract. A method for enhancing anti-wrinkling activity of the extract comprises a step of irradiating radiation to the extract. The extract is prepared by water, alcohol or mixture thereof. The alcohol includes low alcohol of C1-C4. The radiation includes gamma ray, electronic beam, UV or X ray. The pigment includes betanin or isobetanine. A cosmetic composition for anti-wrinkling, skin whitening, or antioxidation contains the red beet extract as an active ingredient.
This is a randomized, double-blind, placebo-controlled Phase III trial with telaprevir in patients with chronic Hepatitis C Virus (HCV), genotype 1, infection who failed prior treatment with standard treatment. Standard treatment is defined as treatment with Peg-INF and RBV. The trial is designed to compare the efficacy, safety, and tolerability of 2 regimens of telaprevir (with and without delayed start) combined with standard treatment versus standard treatment alone. The trial will consist of a screening period of approximately 4 weeks, a 48-week treatment period, and a 24-week follow-up period. Patients will be eligible to enroll in the trial if they (1) had an undetectable HCV Ribonucleic Acid (RNA) level at the end of a prior course of standard treatment but did not achieve a response (viral relapsers), or (2) never had an undetectable HCV RNA level during or at the end of a prior course of standard treatment (non-responders). Approximately 650 patients (350 prior relapsers and 300 prior non-responders) will be randomized in a 2:2:1 ratio to one of 3 treatment groups: Treatment group A will receive telaprevir with standard treatment for 12 weeks; followed by placebo with standard treatment for 4 weeks; followed by standard treatment for 32 weeks. Treatment group B will receive placebo with standard treatment for 4 weeks; followed by telaprevir with standard treatment for 12 weeks; followed by standard treatment for 32 weeks. Treatment group C will receive placebo with standard treatment for 16 weeks; followed by standard treatment for 32 weeks. In both telaprevir regimens (A and B), patients will receive 12 weeks of 750 mg of telaprevir every 8 hours along with 48 weeks of standard treatment. Telaprevir or placebo will be given by mouth at a dose of 750 mg every 8 hours for 16 weeks. Peg-INF will be given as an injection under the skin at a dose of 180 mcg once every week for 48 weeks. RBV will be given by mouth at a dose of either 1000 or 1200 mg (depending on your body weight) two times per day for 48 weeks.
Organisms with three or more complete sets of chromosomes are designated as polyploids. Polyploidy serves as a crucial pathway in biological evolution and enriches species diversity, which is demonstrated to have significant advantages in coping with both biotic stressors (such as diseases and pests) and abiotic stressors (like extreme temperatures, drought, and salinity), particularly in the context of ongoing global climate deterioration, increased agrochemical use, and industrialization. Polyploid cultivars have been developed to achieve higher yields and improved product quality. Numerous studies have shown that polyploids exhibit substantial enhancements in cell size and structure, physiological and biochemical traits, gene expression, and epigenetic modifications compared to their diploid counterparts. However, some research also suggested that increased stress tolerance might not always be associated with polyploidy. Therefore, a more comprehensive and detailed investigation is essential to complete the underlying stress tolerance mechanisms of polyploids. Thus, this review summarizes the mechanism of polyploid formation, the polyploid biochemical tolerance mechanism of abiotic and biotic stressors, and molecular regulatory networks that confer polyploidy stress tolerance, which can shed light on the theoretical foundation for future research.
The patients in this group were supplemented with oral melatonin 0.5 mg/kg/day doses twice daily for one month. After supplementation was completed 0.1 cc sampling from AC.
The comparator agent for this study was the SOC treatment and dosage deemed appropriate by the Investigator. The recommended SOC agents were IV vancomycin, IV clindamycin, and IV semisynthetic penicillins every 24 hours for up to 14 days.
PURPOSE: A composite composition containing organic germanium is provided to ensure thermal stability, strength, hardness, and surface smoothness and to be used as a dental material. CONSTITUTION: A composite composition which is used as a dental material contains 0.6-14 weight% of organic germanium, 83-98 weight% of silica, and 1-3 weight% of metal oxide. The organic germanium contains bis-carboxyethyl-germanium sesquioxide. The metal oxide is selected from SiO_2, Fe_2O_3, Al_2O_3, TiO_2, CaO, MgO, and ZnO. The composite composition is non-crystalline structure. The average grain size is 20-30 nm.
This investigation is to test the interpretation of user instructions of a prototype nasal mask on participants. The clinical investigation will be conducted in New Zealand and participants will interact with the user instructions in a one hour daytime visit. This investigation is designed to evaluate the interpretation by participants of the user instructions. A total number of 20 participants, diagnosed with OSA will be recruited for the trial. The participants will be recruited from the Fisher and Paykel Healthcare Database of subjects (Ethics reference 18/NTA/62).

Fisher and Paykel Healthcare will act as the investigator and sponsor for this investigation. This study will be conducted in accordance with ICH/GCP Guidelines. No deviation from protocol will be implemented without prior review and approval of the sponsor except where it may be necessary to eliminate an immediate hazard to a research participant. In such case, the deviation will be reported to the sponsor (Bhavi Ogra) as soon as possible.
BACKGROUND: This national study investigated hospital quality and patient factors associated with treatment location for breast cancer surgery.
METHODS: By using linked administrative data sets from the English National Health Service, the authors identified all women diagnosed between January 2, 2016, and December 31, 2018, who underwent breast-conserving surgery (BCS) or a mastectomy with or without immediate breast reconstruction. The extent to which patients bypassed their nearest hospital was investigated using a geographic information system (ArcGIS). Conditional logistic regressions were used to estimate the impact of travel time, hospital quality, and patient characteristics.
RESULTS: 22,622 Of 69,153 patients undergoing BCS, 22,622 (32.7%) bypassed their nearest hospital; and, of 23,536 patients undergoing mastectomy, 7179 (30.5%) bypassed their nearest hospital. Women who were younger, without comorbidities, or from rural areas were more likely to travel to more distant hospitals (p < .05). Patients undergoing BCS (odds ratio [OR], 1.85; 95% confidence interval [CI], 1.36-2.50) or mastectomy (OR, 1.52; 95% CI, 1.14-2.02) were more likely to be treated at specialist breast reconstruction centers despite not undergoing the procedure. Patients receiving mastectomy and immediate breast reconstruction were more likely to travel to hospitals employing surgeons who had a media reputation (OR, 2.41; 95% CI, 1.28-4.52). Patients undergoing BCS were less likely to travel to hospitals with shorter surgical waiting times (OR, 0.65; 95% CI, 0.46-0.92). The authors did not observe a significant impact for research activity, hospital quality rating, breast re-excision rates, or the status as a multidisciplinary cancer center.
CONCLUSIONS: Patient choice policies may drive inequalities in the health care system without improving patient outcomes.
The invention discloses a fragrant and appetizing traditional Chinese medicine sachet. The sachet comprises the following components: by weight, 8-15 parts of cortex cinnamomi, 8-15 parts of common fennel, 8-15 parts of syzygium aromaticum, 3-5 parts of fructus amomi, 8-15 parts of rhizoma galangae, 8-15 parts of rhizoma acori graminei, 8-15 parts of pericarpium citri reticulatae, 8-15 parts of radix aucklandiae, 3-5 parts of nutmeg, 8-15 parts of amomum tsaoko, 8-15 parts of perilla leaf, and 8-15 parts of herba eupatorii. The fragrant and appetizing traditional Chinese medicine sachet has medicine smell, and the smell can be inhaled by the mouth and nose. The meridian vessel is unblocked, and the effects of eliminating pathogens to reinforce healthy qi and preventing illness and building fitness are reached. The treatment effect of traditional Chinese medicine is wide, and the sachet has effect of protecting stomach, especially can improve the symptoms of stomachache, belching and the like. The effect is obvious and safe after using the traditional Chinese medicine to regulate qi and harmonize stomach. The sachet uses a plurality of fragrant medicinal materials, and the medicaments in the sachet send out continuous fragrance. The fragrance can be inhaled respiratory tract and stimulates the respiratory mucosa of human, and the medicaments are absorbed to effect.
Medication errors involving lamotrigine have occurred. In particular, the name lamotrigine can be confused with the names of other commonly used medications. Medication errors may also occur between the different formulations of lamotrigine. To reduce the potential of medication errors, write and say lamotrigine extended-release tablets clearly. Depictions of the lamotrigine extended-release tablets can be found in the Medication Guide. Each lamotrigine extended-release tablet has a distinct debossing and is debossed with "W" on one side and "271" on the other side for 25 mg, "W" on one side and "274" on the other side for 50 mg, "W" on one side and "273" on the other side for 100 mg, "W" on one side and "272" on the other side for 200 mg and "W" on one side and "275" on the other side for 300 mg. These distinctive features serve to identify the different presentations of the drug and thus may help reduce the risk of medication errors. Lamotrigine extended-release tablets are supplied in circular, unit-of-use bottles containing 30 tablets and 100 unit dose blister pack. Additionally, Lamotrigine extended-release tablets are also supplied as 500 count bottle pack. The label on the bottle includes a depiction of the tablets which further communicates to patients and pharmacists that the medication is lamotrigine extended-release tablets and the specific tablet strength included in the bottle. To avoid the medication error of using the wrong drug or formulation, patients should be strongly advised to visually inspect their tablets to verify that they are lamotrigine extended-release tablets each time they fill their prescription.
BACKGROUND: Recurrent pneumonia (RP) accounts for 7.7%-9% of childhood pneumonia. Identifying the cause of RP is crucial for infection control and reducing mortality and morbidity. This study aimed to investigate the etiology, risk factors, and diagnostic procedures of RP based on the literature using a diagnostic algorithm.
METHODS: Our study included RP patients aged 0-18 years who were followed up as outpatients or inpatients between 2018 and 2021. Patients were analyzed retrospectively using the national health database. Patients with RP were identified by ICD diagnosis codes. Etiology and risk factors were determined based on the occurrence of RP in the same or different areas.
RESULTS: The rate of RP was found to be 14.4% among the cases of recurrent lower respiratory tract infection. Of these, 27.6% occurred in the same area and 72.4% in different areas. The underlying etiology was identified in 224 of 250 RP patients (89.6%). RP in different areas was mainly due to neuromuscular diseases, whereas asthma, right middle lobe syndrome, and congenital lung or airway structural disease were common causes of RP in the same area. Malnutrition, passive smoke exposure, and prematurity were common risk factors in both groups.
CONCLUSIONS: Systematic etiological investigations should take into account the characteristics of the patient population and geographical region. The use of diagnostic algorithms based on recurrence in the same or different areas is particularly beneficial. Whether asthma is causally related to RP episodes or is a coincidental association due to inadequate differential diagnosis remains unclear.
PURPOSE: To obtain a plaster having a shape memory function, excellent in skin adhesivity, scarcely generating poorly adhesive spaces when plastering, exhibiting excellent motion stretchability during use and durable for the several repetitions of adhesion and peeling cycles. CONSTITUTION: This shape memory plaster is composed of (A) a shape memory plastering body 1, (B) a shape memory supporting body or the combination of the both components. Further, the supporting body having stretchability and air permeability preferably consists of a shape memory alloy fiber cloth or a laminated body of a protein fiber attached with a phosphoramide compound or a copolyester fiber on a fusing binder fiber, and it has a shape memory function at the body temperature. The plastering body 1 is preferably composed of a dissolution agent (e.g. castor oil) for the principal ingredients, a polyacrylic acid or its salt as a form and moisture retaining agent, hydroxylated alumina magnesium, sorbitol, and an absorption-stimulating and flavoring agent (e.g. camphor or menthol).
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by skin barrier dysfunction and chronic inflammatory responses. Reynoutria japonica, known as Huzhang in traditional Chinese Medicine, can enhance blood circulation to eliminate wind pathogens and terminate coughing. Despite pharmacological evidence supporting the efficacy of R. japonica in suppressing edema-induced skin inflammation or connective tissue diseases, its pharmaceutical potential for treating AD-like skin inflammation remains unexplored. This study investigated the possible effects of R. japonica ethanol extract (RJE) on Dermatophagoides farinae extract (DfE)-induced AD-like skin inflammation in NC/Nga mice. To elucidate the underlying mechanisms by which RJE inhibits skin inflammation, we examined the effect of RJE on IFN-γ/TNF-α-induced signal transducer and activator of transcription (STAT) signaling in human epidermal keratinocytes (HEKs) and human dermal fibroblasts (HDFs). Our findings revealed that RJE mitigates DfE-induced AD-like symptoms and skin barrier disruptions in mouse skin lesions. Moreover, RJE attenuated DfE-induced mast cell infiltration and serum levels of inflammatory cytokines (IL-1α, IL-1β, IL-6, IL-23, IFN-γ, TNF-α, and GM-CSF). RJE also inhibited IFN-γ/TNF-α-induced chemokine levels and STAT3 phosphorylation in HEKs and HDFs. Virtual binding analysis of the RJE components suggested that emodin-8-β-D-glucoside binds to Janus kinase (JAK) 1/2, thereby suppressing STAT signaling, which was confirmed by Western blot analysis. In conclusion, our results suggest that RJE may alleviate DfE-induced skin barrier dysfunction by inhibiting JAK/STAT signaling and the proinflammatory immune response through the suppression of inflammatory mediators in AD-like skin disease. These findings suggest that RJE has potential as an effective therapy for AD management.
PROBLEM TO BE SOLVED: To obtain the subject immunosuppressant not producing a serious side effect and excellent in an immunosuppressive action, especially an antilymphocytic action by including a specific linear saccharide as an active ingredient. SOLUTION: This immunosuppressant contains a thermally treated linear saccharide comprising β-1,3-glycoside bonds as an active ingredient. The saccharide preferably comprises a curdlan hydrolysate, especially an acid curdlan hydrolysate using formic acid or the curdlan hydrolysate using β-1,3-glucanase, and has a number-average mol.wt. of 340-4000. The thermal treatment is preferably carried out at a temperature of >=80 deg.C in an aqueous solution. Concretely, a 0.5-5.0wt.% curdlan aqueous solution containing an acid in a concentration of 1-85wt.% is subjected to an acid hydrolysis reaction at a temperature of 70-100 deg.C for about 10min.
Control group B (2017/2018) In a pilot project in July 2017, 46 interns received the phlebotomy proficiency based progression training at CUH. The error rates in the interns in 2017 will be compared to the newly trained interns in 2018 to determine the effectiveness of the training over time. The intervention is the proficiency based progression training programme in phlebotomy.
Surgical treatments for malignant gastric outlet obstructions carry substantial risks and are associated with postoperative morbidity. External compression from advancing tumor or tissue growth through the stent can cause stenosis or re-obstruction. In these patients, the creation of a patent fistula that allows gastric emptying may significantly improve palliation. Minimally invasive techniques that carry no greater risks than enteral stenting may provide a viable palliative treatment. The primary objectives are safety, and successful creation of a gastro-jejunal anastomosis. Secondary objectives are successful resumption or improvement in the ability to tolerate PO feeding, rate of stent migration, and duration of stent and anastomosis patency.
PROBLEM TO BE SOLVED: To obtain the subject emulsion having high stability, comprising a silicone phase containing a cross-linked silicone elastomer and a low-molecular weight silicone fluid and an organic phase containing an organic liquid. SOLUTION: This emulsion comprises a silicone phase containing (A) a cross- linked silicone elastomer and (B) a low-molecular weight silicone fluid and an organic phase containing (C) an organic liquid (preferably ethanol, etc.). Preferably the objective emulsion is composed of a discontinuous organic phase dispersed into a continuous silicone phase. The emulsion in an amount of 100 pts.wt. contains 20-80 wt.% of the silicone phase and 20-80 pts.wt. of the organic phase. The silicone phase contains preferably 0.5-15 pts.wt. of the component A and 85-99.95 pts.wt. of the component B. The component A is preferably a hydrosilylation reaction product of an organosiloxane containing >=2 alkenyl groups on the average, etc., and an organohydrogensiloxane containing >=2 hydrogenated silicon groups on the average.
Inflammation is repressed by interleukin 10 (IL10), a potent anti-inflammatory cytokine, and unchecked inflammation can have detrimental effects on cognition. In healthy older adults enrolled in the Australian Research Council Longevity Intervention (ARCLI) cohort we explored whether a known functional single nucleotide polymorphism (SNP) in the promoter region of IL10, -1082 G/A (rs1800896), was associated with reaction times on computerized cognitive testing that included elements of processing speed (i.e., reaction time). Participants were aged 60-75 years (240 females, 158 males), free of dementia and psychiatric disorders, and provide a blood sample. Processing speed was measured using the Swinburne University Computerized Cognitive Assessment Battery (SUCCAB), which includes measures of reaction time (in milliseconds, ms) on six tasks. Blood-derived DNA was genotyped for the IL10 rs1800896 SNP and presence of the APOE E4 allele. General linear models for each SUCCAB subtest were fitted, with age, sex, education (years), APOE E4 carrier status, and IL10 genotype as independent variables. Carriers of the IL10 AA genotype had significantly slower reaction times on multiple tests compared to carriers of the minor allele (AG, GG) and lower IL10 serum levels. Although IL10 SNPs have not been detected in Alzheimer's disease genome-wide associated studies, these results support further exploration of IL10 mechanisms as a possible resilience factor.
BACKGROUND: Prior research has established a connection between depression and chronic obstructive pulmonary disease (COPD). However, the influence of age and BMI on this association remains unclear.
OBJECTIVES: We used the National Health and Nutrition Examination Survey (NHANES) database to explore the relationship between depression and COPD, and to investigate whether age and Body mass index (BMI) act as moderators in this relationship.
METHODS: We analyzed data from 10,940 participants in the NHANES database. Depression served as the independent variable. COPD status served as the outcome variable. We employed multivariable logistic regression to examine the relationship between depression and COPD.
RESULTS: Of the 10,940 respondents surveyed, about 3.9 % had COPD and 8.5 % had depression. The prevalence of depression in COPD patients was significantly greater than the prevalence of overall respondents (21.1 % VS.8.5 %). We found that the association between depression and COPD was mediated by BMI status. Controlling for other covariates, the association between depression and COPD increased significantly. For the underweight group, the impact of depression on the risk of COPD was lower compared to the normal BMI group.
CONCLUSION: This study confirms a significant association between depression and COPD, with BMI serving as a moderator. These findings enhance our understanding of the complex interplay between depression and COPD and underscore the importance of considering individual physical health characteristics in clinical assessments. The results have significant implications for clinical practice and public health policymaking.
The therapist will instruct the patient on the Guided Imagery protocol and will provide the patient with headphones and an MP-3 player to use for the guided imagery intervention. The patient will listen to the Guided Imagery for 18min 30 sec.